Congress of European Crohn's and Colitis Organisation

Healio brings you the highlights from the Congress of European Crohn's and Colitis Organisation. Refer back to this page often for the latest news from ECCO, perspectives and interviews with leading researchers and clinicians, and to review archives of past meetings.

Meeting News

Real-world Crohn’s study shows genetic link to immunogenicity, biosimilar equivalence

February 21, 2018
Patients with Crohn’s disease who carried an HLA-DQA1*05 haplotype showed an increased risk for developing immunogenicity to anti-tumor…
Meeting News

Age, immunomodulator use increase cancer risk in IBD patients

February 20, 2018
Older patients with inflammatory bowel disease who have recently taken immunomodulators were more likely to have or develop cancer, according to…
Meeting News

Oral JAK1 inhibitor upadacitinib maintains response in Crohn’s through 1 year

February 19, 2018
Many patients with Crohn’s disease who responded to upadacitinib in the induction phase of the phase 2 CELEST study maintained response through…
Meeting News

Patients with ulcerative colitis achieve remission with Otezla

February 19, 2018
Patients with ulcerative colitis treated with Otezla showed significantly higher rates of clinical remission than those who received placebo…
Meeting News

Key bacterial, metabolic changes linked to UC remission after FMT

February 16, 2018
Patients with ulcerative colitis who underwent fecal microbiota transplantation showed consistently increased microbial diversity and altered…
Meeting News

Hyperbaric oxygen therapy benefits hospitalized UC patients

February 23, 2017
Hyperbaric oxygen therapy was effective, safe and well tolerated in hospitalized patients with ulcerative colitis experiencing moderate-to-severe…
Meeting News

FMT for UC induces remission at low dose, short duration

February 22, 2017
Fecal microbiota therapy that was prepared anaerobically from pooled donor material was more effective than placebo at 1 week for inducing remission…
Meeting News

GEMINI: Entyvio in IBD safe, effective through 5 years

February 21, 2017
Long-term use of Entyvio was shown to be safe and effective in patients with moderate-to-severe ulcerative colitis and Crohn’s disease through…
Meeting News

Biosimilar shows comparable safety, efficacy to Remicade in Crohn's

February 20, 2017
Treatment with the infliximab biosimilar, Inflectra, demonstrated comparable safety and efficacy to the originator, Remicade, in a phase 3 randomized…
Meeting News

Cx601 stem cell therapy maintains remission of complex perianal fistulas through 1 year in Crohn's

February 20, 2017
Patients with Crohn’s disease achieved sustained remission of treatment-refractory complex perianal fistulas through 52 weeks after treatment…

Meeting Calendar

European Crohn's and Colitis Organisation Congress

February 15, 2017 - February 18, 2017